https://www.austinpublishinggroup.com/stemcell-research-transplantation/
Pediatricbrain damage of various etiologies, including stroke, and subsequent Cerebral
Palsy (CP) are devastating and debilitating ailments with lifelong sequelae and
high mortality. Unfortunately, there is no causative treatment beyond
symptomatic and supportive care and the estimated lifetime costs per affected
child amount to 800,000 Euro. The enormous number of 17 million people
worldwide that live with cerebral palsy reflects the magnitude of unmet needs
and the personal, medical, and global socioeconomic burden of this brain
disorder.
Butthere is hope. Only recently the first successful cell-based treatment of
arterial ischemic stroke in a child using autologous cord blood mononuclear
cells (Jensen and Hamelmann, 2016 ) and of adult stroke using allogeneic
cord blood mononuclear cells have been reported (Laskowitz et al., 2018 ).
This renders a comprehensive review of the literature mandatory to explore
safety and efficacy of cell-based treatment options for young and elderly
patients alike.
No comments:
Post a Comment